172 related articles for article (PubMed ID: 27660840)
21. Ending sexual HIV transmission: lessons learned from perinatal HIV.
Weber S; Grant RM
J Assoc Nurses AIDS Care; 2015; 26(5):520-5. PubMed ID: 26096627
[No Abstract] [Full Text] [Related]
22. Frequency and Predictors of Tenofovir-diphosphate Detection Among Young Kenyan Women in a Real-world Pre-exposure Prophylaxis Implementation Program.
Pintye J; Kinuthia J; Abuna F; Mugwanya K; Lagat H; Dettinger JC; Odinga D; Sila J; Anderson PL; John-Stewart G; Baeten JM
Clin Infect Dis; 2020 Dec; 71(9):e509-e512. PubMed ID: 32109293
[TBL] [Abstract][Full Text] [Related]
23. Maximizing the Benefits of HIV Preexposure Prophylaxis.
Buchbinder SP
Top Antivir Med; 2018 Apr; 25(4):138-142. PubMed ID: 29689539
[TBL] [Abstract][Full Text] [Related]
24. New PrEP formulation approved…but only for some.
The Lancet Hiv
Lancet HIV; 2019 Nov; 6(11):e723. PubMed ID: 31672278
[No Abstract] [Full Text] [Related]
25. Preexposure Prophylaxis For HIV Prevention: What We Know and What We Still Need to Know for Implementation.
Landovitz RJ
Top Antivir Med; 2015; 23(2):85-90. PubMed ID: 26200708
[TBL] [Abstract][Full Text] [Related]
26. Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010.
Kebaabetswe PM; Stirratt MJ; McLellan-Lemal E; Henderson FL; Gray SC; Rose CE; Williams T; Paxton LA
AIDS Behav; 2015 May; 19(5):758-69. PubMed ID: 25186785
[TBL] [Abstract][Full Text] [Related]
27. Highlights of HIVR4P // Virtual.
Harris P; Henderson R
Lancet HIV; 2021 Mar; 8(3):129. PubMed ID: 33662260
[No Abstract] [Full Text] [Related]
28. Pre-exposure prophylaxis (PrEP) for men who have sex with men in Europe: review of evidence for a much needed prevention tool.
Reyniers T; Hoornenborg E; Vuylsteke B; Wouters K; Laga M
Sex Transm Infect; 2017 Aug; 93(5):363-367. PubMed ID: 27872326
[TBL] [Abstract][Full Text] [Related]
29. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
[TBL] [Abstract][Full Text] [Related]
30. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
Özdener AE; Park TE; Kalabalik J; Gupta R
Expert Rev Anti Infect Ther; 2017 May; 15(5):467-481. PubMed ID: 28322067
[TBL] [Abstract][Full Text] [Related]
31. Pre-exposure prophylaxis is effective at preventing HIV in high risk gay men, study shows.
Mayor S
BMJ; 2015 Sep; 351():h4860. PubMed ID: 26359448
[No Abstract] [Full Text] [Related]
32. Safety of oral tenofovir disoproxil fumarate-based pre-exposure prophylaxis for HIV prevention.
Mugwanya KK; Baeten JM
Expert Opin Drug Saf; 2016; 15(2):265-73. PubMed ID: 26634852
[TBL] [Abstract][Full Text] [Related]
33. Where Were the Women? Gender Parity in Clinical Trials.
Goldstein RH; Walensky RP
N Engl J Med; 2019 Dec; 381(26):2491-2493. PubMed ID: 31665574
[No Abstract] [Full Text] [Related]
34. Uptake of PrEP and condom and sexual risk behavior among MSM during the ANRS IPERGAY trial.
Sagaon-Teyssier L; Suzan-Monti M; Demoulin B; Capitant C; Lorente N; Préau M; Mora M; Rojas Castro D; Chidiac C; Chas J; Meyer L; Molina JM; Spire B;
AIDS Care; 2016; 28 Suppl 1(sup1):48-55. PubMed ID: 26883400
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study.
Nichols BE; Boucher CAB; van der Valk M; Rijnders BJA; van de Vijver DAMC
Lancet Infect Dis; 2016 Dec; 16(12):1423-1429. PubMed ID: 27665989
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of tenofovir disoproxyl fumarate/emtricitabine in a client on pre-exposure prophylaxis after a total gastrectomy.
Roelofsen EE; Wildenbeest S; Mollema FP; Burger DM
AIDS; 2020 Nov; 34(13):1989-1991. PubMed ID: 33009014
[No Abstract] [Full Text] [Related]
37. Once-daily raltegravir with tenofovir disoproxil/emtricitabine as HIV post-exposure prophylaxis following sexual exposure.
Quah SP; McIntyre M; Wood A; Mc Mullan K; Rafferty P
HIV Med; 2021 Feb; 22(2):e5-e6. PubMed ID: 33063431
[No Abstract] [Full Text] [Related]
38. Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial.
Fonsart J; Saragosti S; Taouk M; Peytavin G; Bushman L; Charreau I; Hance A; Goldwirt L; Morel S; Mammano F; Loze B; Capitant C; Clavel F; Mahjoub N; Meyer L; Anderson PL; Delaugerre C; Molina JM
J Antimicrob Chemother; 2017 Feb; 72(2):478-485. PubMed ID: 28073964
[TBL] [Abstract][Full Text] [Related]
39. Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex With Men.
Foster R; McAllister J; Read TR; Pierce AB; Richardson R; McNulty A; Carr A
Clin Infect Dis; 2015 Oct; 61(8):1336-41. PubMed ID: 26123937
[TBL] [Abstract][Full Text] [Related]
40. Awareness and Acceptance of HIV Pre-exposure Prophylaxis among Medical Personnel and Men Who Have Sex with Men in Korea.
Chang HH; Kim SW; Jung H; Lee SA; Park HK; Kim S; Lee JM; Choi JY
J Korean Med Sci; 2018 Mar; 33(12):e91. PubMed ID: 29542300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
